IGM Biosciences to Present at the Jefferies 2020 Healthcare Conference
Rhea-AI Summary
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology firm specializing in engineered IgM antibodies, announced that CEO Fred Schwarzer will present at the Jefferies 2020 Healthcare Conference. The presentation is scheduled for Thursday, June 4, at 10:00 a.m. ET, and will be conducted virtually. Interested participants can access a live webcast through the company’s website, with a replay available for 90 days post-event. IGM Biosciences focuses on advancing IgM antibody technologies, addressing existing manufacturing challenges since its inception in 2010.
Positive
- None.
Negative
- None.
News Market Reaction – IGMS
On the day this news was published, IGMS gained 2.67%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
MOUNTAIN VIEW, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Thursday, June 4 at 10:00 a.m. ET. The conference will be held in a virtual meeting format.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.
Contact:
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com
FAQ
When will IGM Biosciences present at the Jefferies 2020 Healthcare Conference?
Where can I watch the IGM Biosciences presentation at the Jefferies Conference?
What is the main focus of IGM Biosciences?
How long will the webcast of IGM Biosciences' presentation be available?
What date was the IGM Biosciences press release issued?
